Moderna

The article discusses the rapid advancements in biotechnology and AI, emphasizing the need for global biosecurity and biosafety measures to prevent misuse and accidents. It highlights the dual-use nature of gene editing and synthetic biology, the historical use of biological weapons, and the potential for bioterrorism. The article calls for strengthening the Biological Weapons Convention (BWC) and creating international standards for lab safety, DNA synthesis screening, and AI guardrails to manage these risks without stifling innovation.

Union MoS for Health and Family Welfare Smt. Anupriya Singh Patel addresses 19th International Conference of Drug Regulatory Authorities (ICDRA), highlighting India's new regulatory procedures and global collaborations. Dr VK Paul emphasizes the importance of quality medicines post-Covid-19 pandemic.

Dr. Shiwei Duan's team analyzed miRNA's role in cancer, revealing its impact on gene expression, cell growth, and apoptosis. miRNA's complex mechanisms involve interactions with ceRNAs, mRNA, RBPs, and extracellular vesicles, making it crucial for cancer diagnosis and therapy. Challenges like drug resistance are addressed through new technologies and interdisciplinary approaches.

The article discusses the implementation of a Server-Side Rendering (SSR) service entry script, identified by the unique hash 'bc88546b5d3333837a36', which is hidden and intended for specific data processing tasks within a web application.

STAT's First Opinion platform publishes letters in response to essays, fostering discussion. Regina LaRocque disagrees with 'institutional neutrality,' quoting Elie Wiesel. Gerald Keusch praises mRNA vaccine development's scientific foundation. Terry Wilcox advocates for the FDA's Rare Disease Innovation Hub to ensure rare disease patients benefit from advancements.

CRISPR Therapeutics and Moderna, despite share declines, are strong long-term investments due to CRISPR's Casgevy approval and Moderna's diverse mRNA pipeline.

Four years post-COVID-19 peak, Pfizer, Moderna, and Novavax introduce new vaccines targeting strains KP.2 and JN.1. mRNA vaccines from Pfizer and Moderna differ from Novavax's traditional formula, but all aim to enhance protection against evolving COVID-19 strains. The CDC recommends updated vaccines for all over 6 months, emphasizing prevention of severe infection and death.

Meiler lab awarded $46 million to develop a 'super-vaccine' against alphaviruses, leveraging computational techniques and a multidisciplinary team.

GSK's Arexvy vaccine showed 63% efficacy against RSV over three seasons, with a decline to 48% in the third season. The CDC does not recommend a second dose, but GSK suggests revaccination may be needed. Arexvy is the only RSV vaccine with three-season data, and GSK will provide further data to help determine future schedules.

New RSV vaccines for older adults, infants, and pregnant women offer protection against severe RSV, which can be life-threatening for high-risk groups. Vaccines include ABRYSVO®, AREXVY®, and mRESVIA® for adults, nirsevimab for infants, and ABRYSVO for pregnant women to protect newborns.